Cargando…

Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma

A 78-year-old woman with multiple lung nodules, epithelial growth factor receptor (EGFR) exon 20 insertion mutations, and diagnosed with advanced lung adenocarcinoma (cT4N3M1a, stage IVA), was referred to our hospital. She received immune checkpoint inhibitor (ICI) therapy. The therapy showed remark...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horibe, Ryota, Hatakeyama, Taku, Ishikawa, Tatsuru, Sawai, Takeyuki, Hashimoto, Midori, Domen, Hiromitsu, Takakuwa, Yasunari, Satoh, Masaaki, Nishiyama, Kaoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866795/ https://www.ncbi.nlm.nih.gov/pubmed/34393158 http://dx.doi.org/10.2169/internalmedicine.6385-20

Ejemplares similares

Resected thymic large cell neuroendocrine carcinoma: report of a case
por: Domen, Hiromitsu, et al.
Publicado: (2018)

Non‐bacterial cystitis with increased expression of programmed death‐ligand 1 in the urothelium: An unusual immune‐related adverse event during treatment with pembrolizumab for lung adenocarcinoma
por: Ueki, Yohei, et al.
Publicado: (2020)

Alveolar Hemorrhage Caused by the Combination of Immune Checkpoint Inhibitors (ICIs) and Angiogenesis Inhibitors: The Underlying Long-Term Vascular Endothelial Growth Factor (VEGF) Inhibition
por: Shijubou, Naoki, et al.
Publicado: (2022)

Autoimmune Pulmonary Alveolar Proteinosis during the Treatment of Idiopathic Inflammatory Myopathy
por: Shijubou, Naoki, et al.
Publicado: (2022)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202
por: Inomata, Minehiko, et al.
Publicado: (2023)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
por: Ohmori, Tohru, et al.
Publicado: (2021)

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs
por: Yang, Lu, et al.
Publicado: (2020)

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer
por: Liao, Dehua, et al.
Publicado: (2022)

Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study
por: Fujimoto, Keisaku, et al.
Publicado: (2017)

Fulminant amebic colitis in a patient with concomitant cytomegalovirus infection after systemic steroid therapy: A case report
por: Shijubou, Naoki, et al.
Publicado: (2021)

Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report
por: Tokuyasu, Hirokazu, et al.
Publicado: (2019)

Real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests: a study protocol for a cluster parallel-group randomized controlled trial
por: Hirakawa, Akihiro, et al.
Publicado: (2018)

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
por: Fujita, Kohei, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer
por: Chikaishi, Yasuhiro, et al.
Publicado: (2021)

A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer
por: Kato, Yasuhiro, et al.
Publicado: (2019)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

EGFR Mutations and Lung Cancer
Publicado: (2005)

EGFR Signaling in Lung Fibrosis
por: Schramm, Fabian, et al.
Publicado: (2022)

A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer
por: Minemura, Hiroyuki, et al.
Publicado: (2015)

Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report
por: Liu, Qiu-Xia, et al.
Publicado: (2022)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
por: Ninomiya, Kiichiro, et al.
Publicado: (2020)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
por: Shijubou, Naoki, et al.
Publicado: (2021)

Complete Genome Sequence of Multidrug-Resistant Streptococcus pneumoniae Serotype 19F Isolated from an Invasive Infection in Sapporo, Japan
por: Sato, Toyotaka, et al.
Publicado: (2017)

A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
por: OFUJI, KAZUYA, et al.
Publicado: (2014)

Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy
por: Sato, Yota, et al.
Publicado: (2018)

Spontaneous hyperinflation of a giant bulla of the non-ventilated lung during laparoscopic cholecystectomy under one-lung ventilation: a case report
por: Mayahara, Taku, et al.
Publicado: (2022)

Unique MicroRNA and mRNA Interactions in EGFR-Mutated Lung Adenocarcinoma
por: Subat, Sophia, et al.
Publicado: (2018)

Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer
por: Takeuchi, Eiji, et al.
Publicado: (2022)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma
por: Davies, Rhian Siân, et al.
Publicado: (2017)

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations
por: Zhang, Yingyun, et al.
Publicado: (2021)

Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury
por: Yamaoka, Toshimitsu, et al.
Publicado: (2019)

Osimertinib as first-line treatment for recurrent lung cancer patients with EGFR mutation
por: Osoegawa, Atsushi, et al.
Publicado: (2023)

Lung Molecular Cytopathology: EGFR and Beyond
por: Jain, Deepali
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p8rf3t5930qgt1oth8d6hgng7g